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Pharmacy professionals’ perceptions of patient medicines helplines.  
Interview Schedule 
 
 
SECTION 1: Introduction and consent 
 
Thank you for taking the time to speak to me today. Your help with this study is greatly 
appreciated.  
 
This interview will involve me asking you some questions about patient medicines helpline 
services. Overall, the interview is likely to take about 10-20 minutes, although if you would 
like to pause at any point, please let me know. Also, your participation in this study is 
voluntary so if you decide that you no longer want to take part, please also let me know, 
and we can stop the interview.  
 
As mentioned in the information sheet, I would like to audio-record the interview if that’s ok 
with you. The audio recording will be written up word for word so that any identifying 
information which you may mention in the interview can be edited out before the data is 
analysed. This will ensure that your data is anonymous. 
 
Before we begin the interview I need to check that you consent to take part in this study. 
This will involve me reading out some statements to you and checking whether you agree 
with them. I would also like to audio-record the consent process, so that I have a record of 
it.  
 
Are you ready to begin? 
I will start recording this now. 
 
[Start recording the consent process] 
 
First of all, please could you tell me your name and todays date? 
 
[If ‘yes’, continue. If ‘no’, address the concerns and repeat the above consent statement. If 
still ‘no’, explain that it is a requirement of the study. Thank them for their time and end the 
call]. 
 
Do you confirm that you have received information about this study, that you have had the 
opportunity to consider the information, ask questions about the study, and have had these 
answered satisfactorily? 
 
[If ‘yes’, continue. If ‘no’, address the concerns and repeat the above consent statement. If 
still ‘no’, explain that it is a requirement of the study. Thank them for their time and end the 
call]. 
 
Do you understand that your participation is voluntary and that you are free to withdraw 
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from the study at any time without giving a reason? 
 
[If ‘yes’, continue. If ‘no’, address the concerns and repeat the above consent statement. If 
still ‘no’, explain that it is a requirement of the study. Thank them for their time and end the 
call]. 
 
Do you understand that your anonymised data may be retained for at least 10 years in 
accordance with the University of Bath Research Data Policy, and that it may be shared and 
used to support other research in the future? 
 
[If ‘yes’, continue. If ‘no’, address the concerns and repeat the above consent statement. If 
still ‘no’, explain that it is a requirement of the study. Thank them for their time and end the 
call]. 
 
Do you understand that parts of your interview may be used verbatim in future publications 
or presentations and that such quotes will be anonymised (i.e., they will not mention you 
personally)? 
 
[If ‘yes’, continue. If ‘no’, address the concerns and repeat the above consent statement. If 
still ‘no’, explain that it is a requirement of the study. Thank them for their time and end the 
call]. 
 
Do you agree to take part in the study? 
 
[If ‘yes’, continue. If ‘no’, address the concerns and repeat the above consent statement. If 
still ‘no’, explain that it is a requirement of the study. Thank them for their time and end the 
call]. 
 
[Stop recording the consent process] 
 
Thank you for consenting to take part. The consent process is now complete and I have 
stopped recording. I will restart the recording shortly. This is to ensure that the interview 
recording does not contain your name so that the interview data is anonymous. After I press 
record, I will begin by saying your unique participant ID number and the date. 
 
[Start recording] 
 
This is the interview with participant [ID number] on [date]. 
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SECTION 2: Interview questions 
 
 
Q1 To begin, could you please tell me about your role within your NHS Trust’s 
Pharmacy Services? 
Q2 Please could you tell me about your role in relation to the patient medicines 
helpline service? 
 Probe – [For pharmacists, not chief pharmacists] Please could you tell me your 
responsibilities in terms of the patient medicines helpline?  
Probe – [For both pharmacists and chief pharmacists] Did you help to set up the patient 
medicines helpline? If so, please could you describe what your involvement was in 
setting the service up? 
Q3 Please could you describe why your patient medicines helpline service was 
developed? 
 Probe – Research studies? Guidelines? (If so, which?) Awareness of national standards?  
Probe – What do you consider to be the purpose of the patient medicines helpline 
service? (Has its purpose changed over time? If so, in what ways? And Why?) 
Q4 Please could you tell me your thoughts about your patient medicines helpline 
service? 
 For example, meeting its aims.  
Probe - Is there anything you’d like to say about the cost of running the service? 
Probe - Is there anything you’d like to say about how the service may have developed 
since it first began? 
Q5 Please could you tell me what you consider to be the positive aspects of 
operating a patient medicines helpline service? 
 For example… 
Probe – Aspects that are positive for service users.  
Probe – Aspects that are positive for you/the MI team (e.g., learning from adverse 
patient experiences). 
Probe – Aspects that are positive for the hospital/NHS Trust (e.g., learning from adverse 
patient experiences; service improvement initiatives as a result of operating a PMH). 
Probe – Are there any other positive aspects of operating your patient medicines 
helpline which you haven’t mentioned so far? 
Q6 Please could you tell me about any challenges of operating a patient medicines 
helpline service? 
 For example… 
Probe – Aspects that are negative/unhelpful/risks/safety issues for service users. 
Probe – Aspects that are negative/unhelpful for you/the MI team 
Probe – Aspects that are negative/unhelpful for the hospital/NHS Trust. 
Probe – Are there any other challenges of operating your patient medicines helpline 
service which you haven’t mentioned so far? 
Q7 Please can you tell me your thoughts regarding whether the patient medicines 
helpline service meets the needs of patients and carers? 
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 For example, their medicines information needs; their support needs. 
Probe – Please could you explain why?/why not? 
Probe – Is there anything you’d like to say about the uptake of the service? 
(If they mention lack of use: Probe - Do you have any suggestions as to why this might 
be? Probe – Lack of promotion; lack of need; use of other services (if so, which?)). 
Probe – Is there anything you’d like to say about the types of patients/people who use 
the service?  
Probe – Are there any types of patients/people who you think could benefit from the 
service but who don’t typically use it? (If so, who? And why?) 
(If not already known from previous answers) 
Q8 Can you tell me your thoughts regarding the cost-effectiveness of the patient 
medicines helpline? 
 Probe – (If not already known) Please could you say how your helpline service is funded? 
Q9 Please could you tell me about any aspects of your patient medicines helpline 
service that you think could be improved? 
 Probe - If so, why? / In what way? 
 
For example…. 
Probe – Service user access. (Alternative methods? Online chat? Email? Skype / 
facetime?) 
Probe – Helpline availability. 
Probe – Helpline promotion. 
Probe – Procedures you use (e.g., documenting the calls; use of a SOP). 
Probe –IT systems and technology you use.  
Probe – Service user involvement (e.g., including feedback/satisfaction surveys). 
Probe – Mechanisms to feed back to the Trust any issues/errors which become apparent 
during the operation of the service. 
 
Probe – (If not already mentioned) Are you aware of the national standards which are 
available for operating a patient medicines helpline service? Have you used them to 
develop your service? If so, in what ways? 
Q10 Research suggests that sometimes people contact a patient medicines helpline 
service if there is an error with their medicines. Please could you describe any 
process that occurs if a helpline call reveals that an error has been made with a 
patient’s medicines? 
 Probe – Learning from errors / Service improvement initiatives. 
Q11 In what ways do you think the helpline service could be used to improve 
practice, within Pharmacy Services and the wider organisation? 
 Probe – For example, if data is routinely collected about errors, using that information to 
improve practice. 
Probe – [If not yet known] Based upon the examples you’ve given, are these means of 
improvement used at your hospital to improve practice? 
Q12 What qualities do you perceive to be important in order to provide a successful 
patient medicines helpline service? 
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 Probe – (if not obvious) Why are these things important? 
Probe – What staff skills are important? (Training? Standard operating procedures?) 
Q13 How do you see patient medicines helplines at NHS Trusts developing in the 
future? 
 Probe – Developing the service at your NHS Trust, specifically (e.g., additional ways of 
accessing the service; availability of the service; promotion; procedures; IT/technology 
to provide the service; service user involvement). 
Probe – Developments within the UK generally (e.g., move towards regional/shared 
services - Carter Report / 5 year forward review / sustainability and transformation 
plans). 
Probe – Any perceived financial/funding issues in the future. 
Q14 In what ways is local knowledge needed in order to deal with helpline 
enquiries? By ‘local knowledge’, I mean knowledge that is available at your 
hospital or NHS Trust only (e.g., patient records, local policies and procedures, 
advice from clinicians who cared for the patient). 
 Probe – patient records; access to relevant clinical staff; local policies and procedures. 
Q15 What do you think the impact would be if patient medicines helpline services 
became regional or national in the future, instead of local to hospitals? 
 Probe – Impact of this upon the service / quality of the service / the type of information 
that could be provided? 
Q16 Those are all of the questions that I have about patient medicines helpline 
services. Although, is there anything else which you would like to say about 
patient medicines helpline services, which you feel would be important to 
share at this point? 
 
Before we finish, I would like to collect some background information about you. I will stop 
the recording now, so that your interview recording remains anonymised. 
 
 
SECTION 3: Collecting background information and finishing the interview 
 
Before we finish this call, I would like to collect some background information from you if 
that is ok.  
 
[Use the ‘Background Information Data Collection Form’ to collect participants’ background 
information] 
 
Would you like to receive the results of the study, once they become available? They can be 
sent to you by email or post – whichever you prefer. Participants’ contact details are 
destroyed at the end of the study. However, if you would like to receive the results of the 
study, this would mean that I would retain your contact details for a little longer, until the 
results have been sent to you. Your contact details would be stored securely at the 
University of Bath and would only be accessible to the research team, which comprises of 
me and my three supervisors. 
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[If “yes”, collect their desired means of receiving the results – email or postal address. If 
“no”, continue below]. 
 
Thank you once again for your time today, this has been a really helpful conversation.  
 
[End the conversation/call] 
 
 
